Sarcoidosis
Conditions
Keywords
Sarcoidosis, Infliximab, Pulmonary involvement, Remicade
Brief summary
The purpose of this study is to evaluate the safety and effectiveness of infliximab (Remicade) in patients with Chronic Sarcoidosis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.
Detailed description
The purpose of this study is to evaluate the safety and effectiveness of infliximab in the treatment of subjects with sarcoidosis with pulmonary involvement who show symptoms of the disease even though they are currently being treated with medication. Patients will receive either placebo, 3 mg/kg infliximab, or 5 mg/kg infliximab infusions at weeks 0, 2, 6, 12, 18, and 24. Safety evaluations will be performed at specified intervals throughout the study and will consist of laboratory tests, vital signs (such as blood pressure), physical examinations and the occurrence and severity of adverse events as well as other study specific procedures. Patients will receive infusions of Infliximab (Remicade) 3 or 5 mg/kg or placebo at weeks 0, 2, 6, 12, 18 and 24.
Interventions
DRUGInfliximab
Sponsors
Centocor, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have been diagnosed with sarcoidosis at least 1 year prior to entry into the study * Patients must have laboratory test diagnosing sarcoidosis prior to screening * Patients must have a diagnosis of sarcoidosis by chest x- ray
Exclusion criteria
* Patients must not have used any investigational drug within 1 month prior to entering the study * Patients must not have received previous administration of a treatment with any other therapeutic agent targeted at reducing TNF such as pentoxifylline, thalidomide, etanercept, CDP 870, adalimumab, within 3 months prior to screening * Patients must not have received vaccinations within 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in the percent of predicted Full Vital Capacity (FVC) at week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in Saint George's Respiratory Questionnaire total score, Change from baseline in the 6-minute walk distance, Change from baseline in Borg's CR10 dyspnea score, proportion of LuPGA responders at week 24. | — |
Outcome results
None listed